Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 827.21 -6.645 (-0.8%) Market Cap: 91.15 Bil Enterprise Value: 84.05 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 93/100

Regeneron Pharmaceuticals Inc to Purchase Sanofi's Stake in Libtayo Investor Call Transcript

Jun 02, 2022 / 12:30PM GMT
Release Date Price: $654.77
Operator

Welcome to the Regeneron Pharmaceutical Analyst and Investor Conference Call to discuss with Regeneron's intent to acquire global rights to Libtayo. My name is Norma, and I will be the operator for today's conference.

(Operator Instructions)

Please note that today's conference is being recorded. I will now turn the call over to Ryan Crowe, Vice President, Investor Relations. You may begin.

Ryan Crowe
Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Norma. Good morning, good afternoon and good evening to everyone listening around the globe. Thank you for joining us on short notice. Welcome to our investor call to discuss our intent to acquire global rights to Libtayo from Sanofi. An archive of this webcast will be available on our Investor Relations website shortly after the call ends. Joining me today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President and Head of Commercial; and Bob Landry,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot